Deutenzalutamide - Hinova Pharmaceuticals
Alternative Names: Deuterated enzalutamide; Enzalutamide deuterated; HC 1119Latest Information Update: 30 Aug 2024
Price :
$50 *
At a glance
- Originator Hinova pharmaceuticals
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Fluorobenzenes; Imidazoles; Imidazolidines; Nitriles; Organic deuterium compounds; Small molecules; Thiones
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Prostate cancer
- Phase III COVID 2019 infections
- No development reported Breast cancer
Most Recent Events
- 15 Aug 2024 Hinova Pharmaceuticals terminates phase-III clinical trials in Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) in Australia, Austria, US, Netherlands, Canada, Belgium, Denmark, Denmark, Finland, France, Germany, Italy, Poland, Russia, Spain, United Kingdom (PO) due to various factors including prolonged duration and enrollment challenges (EudraCT2019-001144-22) (NCT03850795)
- 10 Jul 2023 Preregistration for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO) (Hinova Pharmaceuticals, pipeline July 2023)
- 02 Jun 2023 Efficacy and adverse events data from a phase III trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)